Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Ajinomoto, Interprotein Sign Joint R&D Agreement for PPI Inhibitors
November 22, 2011
- Sanofi, Nichi-Iko to Copromote Latter's Generic Drugs
November 22, 2011
- US FDA Accepts NDA for Once-monthly Depot Formulation of Abilify
November 22, 2011
- US Court Issues Amended Ruling in Litigation Between Asahi Kasei Pharma, Actelion
November 22, 2011
- OncoTherapy to File for Therapeutic Pancreatic Cancer Vaccine in Sept. 2012
November 22, 2011
- Sawai, Nichi-Iko Boost Inventory Ahead of Expected PAL Amendment
November 21, 2011
- FDA Extends Action Date for Takeda’s Alogliptin for 3 Months
November 21, 2011
- Eli Lilly Japan to Provide Alimta to Research for Free
November 21, 2011
- Novartis, Eisai to Copromote Onbrez
November 21, 2011
- MTPC, JRCS to Postpone Integration of Plasma Fractionation Products Business to Oct 2012
November 21, 2011
- Daiichi Sankyo Forms Subsidiary in China to Manage Local Operations
November 21, 2011
- Shionogi, Shire Enter into License Agreement for Codevelopment of ADHD Treatments
November 21, 2011
- Nihon Chouzai to Introduce Electronic Drug Notebooks at All Stores
November 21, 2011
- US FDA Approves VEGF Trap-Eye for Wet AMD: Bayer Healthcare
November 21, 2011
- GSK, Daiichi Sankyo Launch Rotarix for Prevention of Rotavirus Gastroenteritis in Children
November 21, 2011
- CMIC to Establish Holding Company “CMIC HD”
November 18, 2011
- “Steady Sales in 1st Half as Result of Strict Price Lock System Operation”: President Hamada of Toho HD
November 18, 2011
- Bayer to Expand Asian Business, Focus on Chinese Market
November 18, 2011
- Teva to Merge Taiyo, Kowa-Teva, Establish “Teva Pharma Japan” in Mid-2012
November 18, 2011
- Intellim Corp. to Strengthen Contract Research System in Field of Oncology
November 18, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…